Onset and depth of response with abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis, including prominent head-and-neck dermatitis: A post hoc analysis of the head-to-head phase 3 JADE DARE study

By afschroeder • February 23, 2026

Armstrong AW, Gooderham MJ, Eyerich K, Reich K, Blauvelt A, Hong HC, Edwards RA, Bonfanti G, Clibborn C, Biswas P, Chan G, Feeney C, Güler E. Onset and depth of response with abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis, including prominent head-and-neck dermatitis: A post hoc analysis of the head-to-head phase 3 JADE DARE study. J Am Acad Dermatol. 2026 Feb 20:S0190-9622(26)00284-7. doi: 10.1016/j.jaad.2026.02.066. Epub ahead of print. PMID: 41724439.

Tags: abrocitinib, atopic dermatitis, Dermatology, Dupilumab, head-to-head trial, high-threshold responses, Publications, Quality of Life, super-response

A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023

Maverakis Ramirez N, Jaeger ZJ, Lee DJ. A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023. Cureus. 2026 Jul 8;18(7):e112280.[...]

Multicytokine-based transcriptome-wide association study for 7 inflammatory skin disorders identifies candidate causal genes in keratinocytes

Zhang H, Patrick MT, Sarkar MK, Bogle R, Li Q, Uppala R, Perez White BE, Petukhova L, Dand N, Stuart PE, Christiano AM, Simpson MA,[...]

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials

Okubo Y, Morita A, Tada Y, Imafuku S, Armstrong AW, Blauvelt A, Vaile J, Popmihajlov Z, Li J, Sawant R, Habiro K, Tsuritani K, Ohtsuki[...]